Study to Assess Safety of HDP-101 in Patients With Relapsed Refractory Multiple Myeloma

Active:	Yes
Cancer Type:	Multiple Myeloma	NCT ID:	NCT04879043
Trial Phases:	Phase I Phase II	Protocol IDs:	HDP-101-01 (primary) NCI-2021-04304
Eligibility:	18 Years and older, Male and Female	Study Type:	Treatment
Study Sponsor:	Heidelberg Pharma AG
NCI Full Details:	http://clinicaltrials.gov/show/NCT04879043

Summary

This study will assess the safety, tolerability, pharmacokinetics (PK) and the
therapeutic potential of HDP-101 in patients with plasma cell disorders including
multiple myeloma.

Objectives

The study will consists of two parts: a Part 1 dose escalation phase and a Part 2a
expansion phase for safety, tolerability, PK, PD, and clinical activity testing. The
study will enroll subjects with relapsed/refractory MM or other plasma cell disorders
expressing BCMA. An adaptive 2-parameter Bayesian logistic regression model (BLRM) for
dose-escalation with overdose control will be used in the dose-escalation phase for
determination of the MTD or the RP2D. Dose-expansion phase of the study aims to collect
preliminary evidence of antitumor activity and to confirm the safety of the HDP-101 as a
monotherapy.

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.